Horizon Pharma (HZNP) Tops Q3 EPS by 7c; Raises Outlook

Horizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.24, $0.07 better than the analyst estimate of $0.17. Revenue for the quarter came in at $75.1 million versus the consensus estimate of $73.17 million.

Horizon Pharma sees FY2014 revenue of $280-290 million, versus prior guidance of $270-280 million and the consensus of $277.6 million.

Horizon Pharma sees FY2015 revenue of $425-450 million, versus prior guidance of $380-405 million and the consensus of $389.5 million.

"Our strong operational execution in the third quarter, along with our recent business development activity, gives us great confidence as we close out this year," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "Our year-to-date performance, along with expectations for ACTIMMUNE and our recently announced acquisition of PENNSAID 2%, allow us to increase our guidance for both 2014 and 2015."

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Reading (RDI) Tops Q2 EPS by 4c